Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
ALK
BRAF
EGFR
ERBB2
KRAS
Lung adenocarcinoma
MET
Non-small cell lung cancer
PIK3CA
RET
ROS1
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
13
11
2018
accepted:
01
02
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Molecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status in a representative cohort of Swiss patients with lung adenocarcinoma and to correlate the mutational status with clinicopathological patient characteristics. All patients who underwent molecular testing of newly diagnosed lung adenocarcinoma during a 4-year period (2014-2018) were included. Molecular analyses were performed with Sanger sequencing (n = 158) and next generation sequencing (n = 311). ALK, ROS1 and RET fusion gene analyses were also performed with fluorescence in situ hybridization and immunohistochemistry/immunocytochemistry. Demographic and clinical data were obtained from the medical records. Of 469 patients with informative EGFR mutation analyses, 90 (19.2%) had EGFR mutations. KRAS mutations were present in 33.9% of the patients, while 6.0% of patients showed ALK rearrangement. BRAF, ERBB2, MET and PIK3CA mutations and ROS1 and RET rearrangements were found in 2.6%, 1.9%, 1.9%, 1.5%, 1.7% and 0.8% of the patients, respectively. EGFR mutation was significantly associated with female gender and never smoking status. ALK translocations were more frequent in never smokers, while KRAS mutations were more commonly found in ever smokers. The association between KRAS mutational status and female gender was statistically significant only on multivariate analysis after adjusting for smoking. The EGFR mutation rate in the current study is among the higher previously reported mutation rates, while the frequencies of KRAS, BRAF, ERBB2 and PIK3CA mutations and ALK, ROS1 and RET rearrangements are similar to the results of previous reports. EGFR and KRAS mutations were significantly associated with gender and smoking. ALK rearrangements showed a significant association with smoking status alone.
Sections du résumé
BACKGROUND
BACKGROUND
Molecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status in a representative cohort of Swiss patients with lung adenocarcinoma and to correlate the mutational status with clinicopathological patient characteristics.
METHODS
METHODS
All patients who underwent molecular testing of newly diagnosed lung adenocarcinoma during a 4-year period (2014-2018) were included. Molecular analyses were performed with Sanger sequencing (n = 158) and next generation sequencing (n = 311). ALK, ROS1 and RET fusion gene analyses were also performed with fluorescence in situ hybridization and immunohistochemistry/immunocytochemistry. Demographic and clinical data were obtained from the medical records.
RESULTS
RESULTS
Of 469 patients with informative EGFR mutation analyses, 90 (19.2%) had EGFR mutations. KRAS mutations were present in 33.9% of the patients, while 6.0% of patients showed ALK rearrangement. BRAF, ERBB2, MET and PIK3CA mutations and ROS1 and RET rearrangements were found in 2.6%, 1.9%, 1.9%, 1.5%, 1.7% and 0.8% of the patients, respectively. EGFR mutation was significantly associated with female gender and never smoking status. ALK translocations were more frequent in never smokers, while KRAS mutations were more commonly found in ever smokers. The association between KRAS mutational status and female gender was statistically significant only on multivariate analysis after adjusting for smoking.
CONCLUSION
CONCLUSIONS
The EGFR mutation rate in the current study is among the higher previously reported mutation rates, while the frequencies of KRAS, BRAF, ERBB2 and PIK3CA mutations and ALK, ROS1 and RET rearrangements are similar to the results of previous reports. EGFR and KRAS mutations were significantly associated with gender and smoking. ALK rearrangements showed a significant association with smoking status alone.
Identifiants
pubmed: 30744664
doi: 10.1186/s13000-019-0789-1
pii: 10.1186/s13000-019-0789-1
pmc: PMC6371584
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Références
Cancer. 2001 Sep 15;92(6):1525-30
pubmed: 11745231
Cancer Res. 2005 Mar 1;65(5):1642-6
pubmed: 15753357
Lung Cancer. 2006 Nov;54(2):209-15
pubmed: 16930767
Int J Cancer. 2006 Dec 1;119(11):2586-91
pubmed: 16988931
Cancer Genet Cytogenet. 2007 Mar;173(2):107-13
pubmed: 17321325
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Lung Cancer. 2008 Aug;61(2):163-9
pubmed: 18242762
Mod Pathol. 2008 May;21 Suppl 2:S37-43
pubmed: 18437172
Clin Cancer Res. 2008 Jul 1;14(13):4275-83
pubmed: 18594010
Cancer Res. 2008 Sep 1;68(17):6913-21
pubmed: 18757405
Clin Cancer Res. 2008 Sep 15;14(18):5731-4
pubmed: 18794081
Clin Cancer Res. 2008 Oct 15;14(20):6618-24
pubmed: 18927303
Cancer Res. 2008 Nov 15;68(22):9375-83
pubmed: 19010912
J Thorac Oncol. 2009 Jan;4(1):5-11
pubmed: 19096300
Cancer. 2009 Apr 15;115(8):1723-33
pubmed: 19170230
Onkologie. 2010;33(5):231-8
pubmed: 20502057
J Thorac Oncol. 2010 Aug;5(8):1130-5
pubmed: 20559149
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
J Thorac Oncol. 2010 Dec;5(12):1922-32
pubmed: 21155183
J Thorac Oncol. 2011 May;6(5):947-50
pubmed: 21623266
Lung Cancer. 2012 Jun;76(3):403-9
pubmed: 22129856
Mol Cancer Ther. 2012 Feb;11(2):485-91
pubmed: 22135231
Lung Cancer. 2012 Jun;76(3):280-5
pubmed: 22197614
J Thorac Oncol. 2012 Apr;7(4):672-80
pubmed: 22425916
Clinics (Sao Paulo). 2012;67(5):419-24
pubmed: 22666783
Clin Cancer Res. 2012 Sep 15;18(18):4910-8
pubmed: 22761469
Genome Res. 2012 Nov;22(11):2109-19
pubmed: 22975805
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
Clin Cancer Res. 2012 Dec 15;18(24):6771-83
pubmed: 23136191
J Clin Oncol. 2012 Dec 10;30(35):4352-9
pubmed: 23150706
Lancet Oncol. 2013 Jan;14(1):38-47
pubmed: 23200175
Diagn Mol Pathol. 2013 Jun;22(2):70-5
pubmed: 23628817
Onco Targets Ther. 2013 May 07;6:497-502
pubmed: 23674897
Lung Cancer. 2013 Sep;81(3):347-53
pubmed: 23806795
Oncologist. 2013;18(7):865-75
pubmed: 23814043
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
Exp Lung Res. 2013 Oct;39(8):328-35
pubmed: 23919423
Int J Oncol. 2013 Oct;43(4):1045-51
pubmed: 23934203
Oncol Lett. 2013 Nov;6(5):1207-1212
pubmed: 24179496
PLoS One. 2014 Feb 12;9(2):e88291
pubmed: 24533074
Mol Cancer. 2014 Jul 21;13:176
pubmed: 25047660
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Thorac Oncol. 2014 Sep;9(9):1406-10
pubmed: 25122436
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
PLoS One. 2015 Feb 23;10(2):e0117333
pubmed: 25706305
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
J Thorac Oncol. 2015 Sep;10(9):1370-1374
pubmed: 26291014
Acta Oncol. 2016;55(2):149-55
pubmed: 26313507
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
JAMA Oncol. 2016 Jun 1;2(6):805-12
pubmed: 27100819
Oncotarget. 2016 Jul 5;7(27):41691-41702
pubmed: 27223439
Swiss Med Wkly. 2016 Jul 11;146:w14327
pubmed: 27400130
Cancer Cytopathol. 2017 Jan;125(1):30-40
pubmed: 27636102
Diagn Pathol. 2016 Sep 21;11(1):90
pubmed: 27655296
J Thorac Oncol. 2017 Aug;12(8):1233-1246
pubmed: 28502721
Eur J Cancer Care (Engl). 2017 Nov;26(6):null
pubmed: 28557060
Cancer Sci. 2017 Dec;108(12):2487-2494
pubmed: 28949084
Virchows Arch. 2018 Apr;472(4):581-588
pubmed: 29198034
Oncotarget. 2017 May 20;8(57):96684-96696
pubmed: 29228562
Pathol Res Pract. 2018 Apr;214(4):572-578
pubmed: 29580750
Ann Transl Med. 2018 Apr;6(8):142
pubmed: 29862231
Mol Med Rep. 2018 Aug;18(2):2191-2197
pubmed: 29956783
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lung Cancer. 2018 Oct;124:53-64
pubmed: 30268480